Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NARA study of alternate-day relugolix before surgery for uterine fibroids
jRCTs051230078Recruiting
- Sponsor
- Nara Medical University
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tissue-plasminogen activator in Fibromyoma (LM), sponsored by Nara Medical University. Primary endpoint: Change rate of leiomyoma volume before and after relugolix administration. Started Oct 2023; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCTs051230078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230078.